Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
47.47 USD | -2.39% | -7.65% | +33.42% |
Business Summary
Number of employees: 290
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100.0
%
| 5 | 100.0 % | 4 | 100.0 % | -15.28% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States and Australia
100.0
%
| 5 | 100.0 % | 4 | 100.0 % | -15.28% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Stephen Betz
FOU | Founder | 58 | 07-12-31 |
Scott Struthers
FOU | Founder | 62 | 07-12-31 |
Marc Wilson
DFI | Director of Finance/CFO | 45 | 17-12-31 |
Dana Pizzuti
CTO | Chief Tech/Sci/R&D Officer | 69 | 22-09-29 |
Matt McDowell
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jeff Knight
COO | Chief Operating Officer | 53 | 21-08-29 |
Chris Robillard
PRN | Corporate Officer/Principal | - | 22-03-20 |
Garlan Adams
LAW | General Counsel | - | 21-06-15 |
Michael Monahan
LAW | General Counsel | - | 18-05-31 |
Brian Russell
PRN | Corporate Officer/Principal | - | 22-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Wendell Wierenga
CHM | Chairman | 76 | 15-09-30 |
Matthew Fust
BRD | Director/Board Member | 59 | 18-01-31 |
Director/Board Member | 71 | 20-09-02 | |
Caren Deardorf
BRD | Director/Board Member | 59 | 22-03-10 |
Director/Board Member | 60 | 22-01-02 | |
Weston Nichols
BRD | Director/Board Member | 39 | 18-01-31 |
Scott Struthers
FOU | Founder | 62 | 07-12-31 |
Stephanie Okey
BRD | Director/Board Member | 64 | 19-07-14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 78,859,510 | 75,716,938 ( 96.01 %) | 0 | 96.01 % |
Company contact information
Crinetics Pharmaceuticals, Inc.
6055 Lusk Boulevard
92121, San Diego
+858 450 6464
http://www.crinetics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.42% | 3.74B | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- CRNX Stock
- Company Crinetics Pharmaceuticals, Inc.